Rhumbline Advisers Aclaris Therapeutics, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$1.01 - $1.36 $55,767 - $75,092	-55,215 Reduced 56.79%	42,005 $46,000
Q1 2024 May 09, 2024	BUY	$0.92 - $1.44 $1,352 - $2,116	1,470 Added 1.54%	97,220 $120,000
Q4 2023 Feb 08, 2024	SELL	$0.64 - $6.49 $4,277 - $43,379	-6,684 Reduced 6.53%	95,750 $100,000
Q3 2023 Nov 09, 2023	SELL	$6.56 - $10.95 $12,418 - $20,728	-1,893 Reduced 1.81%	102,434 $701,000
Q2 2023 Aug 08, 2023	BUY	$7.89 - $10.64 $130,745 - $176,315	16,571 Added 18.88%	104,327 $1.08 Million
Q1 2023 May 11, 2023	BUY	$7.07 - $17.95 $13,390 - $33,997	1,894 Added 2.21%	87,756 $710,000
Q4 2022 Feb 14, 2023	BUY	$14.33 - $18.37 $33,962 - $43,536	2,370 Added 2.84%	85,862 $1.35 Million
Q3 2022 Nov 10, 2022	BUY	$13.07 - $18.22 $150,213 - $209,402	11,493 Added 15.96%	83,492 $1.31 Million
Q2 2022 Aug 11, 2022	BUY	$10.16 - $17.08 $170,738 - $287,029	16,805 Added 30.45%	71,999 $1.01 Million
Q1 2022 May 12, 2022	BUY	$9.74 - $17.92 $82,488 - $151,764	8,469 Added 18.13%	55,194 $952,000
Q4 2021 Feb 10, 2022	BUY	$12.27 - $18.49 $17,472 - $26,329	1,424 Added 3.14%	46,725 $679,000
Q3 2021 Nov 12, 2021	BUY	$13.38 - $18.8 $45,960 - $64,578	3,435 Added 8.2%	45,301 $815,000
Q2 2021 Aug 05, 2021	BUY	$17.08 - $29.6 $715,071 - $1.24 Million	41,866 New	41,866 $735,000
Q2 2020 Aug 13, 2020	SELL	$1.04 - $1.73 $53,691 - $89,312	-51,626 Closed	0 $0
Q1 2020 May 06, 2020	SELL	$0.75 - $2.18 $3,276 - $9,522	-4,368 Reduced 7.8%	51,626 $54,000
Q4 2019 Feb 05, 2020	BUY	$1.02 - $1.97 $1,973 - $3,811	1,935 Added 3.58%	55,994 $106,000
Q3 2019 Oct 23, 2019	BUY	$0.79 - $2.47 $3,289 - $10,285	4,164 Added 8.35%	54,059 $58,000
Q2 2019 Aug 14, 2019	BUY	$2.13 - $7.06 $8,377 - $27,766	3,933 Added 8.56%	49,895 $109,000
Q1 2019 May 01, 2019	BUY	$5.63 - $7.84 $36,437 - $50,740	6,472 Added 16.39%	45,962 $275,000
Q4 2018 Jan 31, 2019	BUY	$6.3 - $15.4 $83,594 - $204,342	13,269 Added 50.6%	39,490 $292,000
Q3 2018 Nov 07, 2018	SELL	$14.38 - $20.89 $13,013 - $18,905	-905 Reduced 3.34%	26,221 $381,000
Q2 2018 Aug 06, 2018	BUY	$16.46 - $20.33 $81,361 - $100,491	4,943 Added 22.28%	27,126 $542,000
Q1 2018 May 02, 2018	BUY	$17.08 - $25.64 $1,537 - $2,307	90 Added 0.41%	22,183 $389,000
Q4 2017 Feb 09, 2018	SELL	$21.47 - $27.8 $41,973 - $54,349	-1,955 Reduced 8.13%	22,093 $545,000
Q3 2017 Nov 06, 2017	BUY	$23.02 - $28.8 $553,584 - $692,582	24,048	24,048 $621,000

Others Institutions Holding ACRS

# of Institutions

Shares Held

50.7M

Call Options Held

30.6K

Put Options Held

Bml Capital Management, LLC Zionsville, IN

14.3M
Shares

$54.2 Million
9.64% of portfolio
Vanguard Group Inc Valley Forge, PA

4.69M
Shares

$17.8 Million
0.0% of portfolio
D. E. Shaw & Co., Inc. New York, NY

3.37M
Shares

$12.8 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

3.01M
Shares

$11.4 Million
0.0% of portfolio
Rock Springs Capital Management LP Baltimore, MD

2.75M
Shares

$10.5 Million
0.11% of portfolio

View Full List

About Aclaris Therapeutics, Inc.

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $253M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

More about ACRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account